As an example for studies of contacts involved in complex biological systems, peptide ligands that bind to the core antigen of hepatitis B virus (HBcAg) have been selected from a random hexapeptide library displayed on filamentous phage. Affinity-purified phage bearing aa sequence LLGRMK, or some related sequences, bound fulllength or truncated HBcAg but did not bind denatured HBcAg. The long (L), but not the short (S), hepatitis B virus envelope polypeptide, when synthesized in an in vitro system, bound firmly to HBcAg, indicating that interaction between HBcAg and the pre-S region of the L polypeptide is critical for virus morphogenesis. This interaction was inhibited by peptide ALLGRMKG, suggesting that this and related small molecules may inhibit viral assembly.
and is also by far the most abundant form in the 22-nm particles of HBsAg that are found in great excess over the virus in the plasma of infected individuals.
The HBV core antigen (HBcAg) can be synthesized efficiently in Escherichia coli (13, 14) , where it assembles to form 27-nm particles equivalent morphologically to those found in the liver of infected individuals (15) . This provides a convenient source of HBcAg and derivatives of it for identification of peptide sequences carried by fusion phage that bind the antigen. The L and S HBsAg. forms were synthesized in cell-free systems for analysis of their interaction with HBcAg and its inhibition by antibodies and peptides identified via the fusion phage libraries.
Coliphage fd carrying random hexapeptide sequences in their gpIII protein have emerged as powerful tools for studies of ligand binding in the absence of structural or even sequence information (1) (2) (3) . These phage have found use in a range of studies-including mapping the binding sites of antibodies (1, 3, 4) , a chaperone protein (5) , and cell-surface receptors (6) .
As a test system for the identification of contact regions between the components of complex biological structures such as organelles, viruses, or other multicomponent assemblies, we have used such fusion phage to explore interactions between the core and surface antigen components of hepatitis B virus (HBV). The results offer a guide to a critical stage of viral morphogenesis and approaches to its inhibition by small molecules, derived from short peptides, resembling the contact regions.
HBV consists of a nucleocapsid, the small 3.2-kb DNA genome, and the viral polymerase enclosed by the core antigen of the virus, surrounded in turn by the HBV viral surface antigen (HBsAg) . The viral envelope contains three different, but related, HBsAg polypeptides, which overlap extensively from their carboxyl termini and arise from variable use of initiation triplets at different points within a continuous open reading frame. The long polypeptide (L polypeptide) is the product of the entire reading frame and comprises the pre-Sl domain of 108 amino acids (or 119, depending on virus subtype) at its amino terminus followed by the pre-S2 domain of 55 amino acids and the short polypeptide (S polypeptide) region of 226 amino acids. The medium-length polypeptide (M polypeptide) has the pre-S2 domain at its amino terminus followed by the S region, whereas the S polypeptide, which is the most abundant form, consists of only the S region. The pre-S regions are believed to play a role in both viral assembly (7, 8) and attachment to the host cell (9) (10) (11) . The Plasmids pMDHBs3 and pMDHBs4, encoding the L and S forms of HBsAg, respectively, were used as templates for in vitro transcription reactions. Both contained a T7 RNA polymerase promoter followed by a 586-bp copy of the encephalomyocarditis virus RNA 5' noncoding region (ref. 16 ; Novagen), 5' to the HBsAg coding regions that were generated as EcoRI-Sal I DNA fragments from plasmid pHBV130 (17) . PCR amplification was used to create EcoRI targets by double mutations at either A922 -_ G and T923 -> A or G14-* A and G1419 C for the L-and S-coding fragments, respectively, and a downstream site for Sal I (A2274 -> G) common to both fragments.
Purification of Particles Comprising Full-Length or Truncated HBeAg. Purification of HBcAg from E. coli RB 791 harboring various plasmids (18, 19) was as described (20) , except that the cell extract was precipitated by ammonium sulfate (35% saturation), dialyzed against TBS (50 mM Tris HCl, pH 7.5/150 mM NaCl), applied to 8-40% sucrose gradients (12 ml; TBS), and centrifuged at 100,000 x g (TH641 rotor, Sorvall) for (21) . Amplified eluates were subjected to two further rounds of affinity enrichment. DNA was isolated from individual phage clones (21) , and the nucleotide sequence was determined (22) by using primer 5'-AGTTTT-GTCGTCTTTCC-3'. Selected phage plaques were amplified in 500-ml cultures and purified by PEG precipitation and equilibrium centrifugation in 31% (wt/wt) CsCl/TBS (21) .
Phage-Binding Assay in Solution. HBcAg at various concentrations (0.3-10 ,uM) was incubated at 6°C for 18 hr with fusion phage Bi (109 pfu/ml) in TBS/BSA (0.2 mg/ml)/NaN3 (0.02%). Aliquots (100 ,lI) of each mixture were transferred to polystyrene wells (no. 2585, Costar) that had been coated with HBcAg (20 ,ug/ml in PBS; 125 p,l per well). After 1 hr at 6°C the wells were washed 10 times with TBS/BSA at 0.2 mg/ml. Bound phage were recovered and titered as described in the previous section. All assays were done in triplicate. The HBcAg concentration range was 1.58-50 ,uM for experiments with phage B2 and B3 and was 0.63-20 ,uM for experiments with phage B4. For peptide inhibition experiments, fusion phage (109 pfu/ml; 200 ,lI) were incubated with various concentrations of peptide (1 mM-10 nM) in HBcAg-coated wells for 90 min at 6°C.
In Vitro Transcription, Translation, and Translocation. Templates for transcription were linearized by digestion with Sal 1. Transcription reactions were done as described (23) Immunoprecipitations. Translation mixture (5 ,lI) was diluted to 200 ,l with NET-gel buffer (50 mM Tris HCl, pH 7.5/150 mM NaCl/0.1% Nonidet P-40/1 mM EDTA/0.25% gelatin/0.02% NaN3), containing 2 mM dithiothreitol. Either undiluted anti-HBsAg (a 1:1 mixture of anti-native and antidenatured HBsAg sera) or a 1:10 dilution of anti-HBcAg rabbit polyclonal serum (1.5 ,ul) was added to the mixture. Immunoprecipitation with protein A-Sepharose and analysis by SDS/PAGE were as described (24) .
Inhibition of Membrane-Inserted L-Protein Binding to HBcAg by Antibodies and Peptides. Canine pancreatic microsomal membranes containing 35S-labeled L protein were purified by layering the translation mixture (60 pjl) on a 4-ml step gradient of 1-ml intervals of 77% (wt/vol), 30%, 20%, and 10% sucrose containing 20 (1) . Three rounds of affinity selection against HBcAg resulted in the enrichment of specific fusion phages. In two experiments, A and B, the phage library was screened against truncated HBcAg (aa 3-148) and in a third experiment, C, against BSA. In experiment A the washing buffer used during affinity purification contained 0.15 M NaCl, whereas for experiments B and C this concentration was increased to 0.5 M. In the case of experiment B, 10-3% of phage bound to the membrane in the first round of panning, and this binding increased to 1% in the third panning. No increases were observed in experiments A and C.
The peptides carried by phage cloned from various eluent pools are shown in Table 1 . Panning the phage library against BSA gave apparently random peptide sequences (experiment C). This result is as expected because the library had been incubated with a buffer containing BSA, before panning, to eliminate phage that bind BSA. No recognizable consensus sequence was observed in initial affinity selection of the library against HBcAg (experiment A), but a strong conservation of sequence between selected phage clones became apparent when the selection was made more stringent by washing at higher salt concentration. Of 46 independent clones, 36 were very similar (experiment B) with the sequence LLGRMK (clone B1) predominating, followed by the somewhat similar sequence YLLRFR (clone B2). Conservative variations of Bi were also observed with the methionine at position 5 substituted by leucine or phenylalanine and the lysine at position 6 substituted by arginine.
Specificity of Selected Phage for HBcAg. To show that the solid-phase selection system for phage that bind HBcAg 
denatured form, cloned phage were incubated in solution with various concentrations of freshly prepared HBcAg and then placed in polystyrene wells coated with HBcAg particles. Fig. 1A shows that preincubation with increased concentrations of HBcAg progressively reduced the availability of phage for binding to HBcAg on the solid phase, proving that the phage did indeed recognize intact HBcAg particles. Relative dissociation constants (KdRel) between the various fusion phage and HBcAg in solution (Table 2) were calculated by curve-fitting the data in Fig. 1 to a hyperbolic function (Sigma Plot, Jandel, Erkrath, Germany). This method follows that used for measurement of affinity constants in solution between antigen-antibody complexes (25) and will be described in detail elsewhere. The equilibrium dissociation constants obtained are relative numbers because both HBcAg and the phage are multivalent. Table 2 shows the order of binding of the hexapeptide ligands to HBcAg to be LLGRMK > LLGRFK > LLGRLK > YLLRFR. Fig. 1B shows that phage Bi bound to full-length HBcAg (aa 3-183) as efficiently as to truncated HBcAg but did not bind to heat-denatured, truncated HBcAg. The selected fusion phage may thus recognize a conformational feature, perhaps a cleft, within the native, particulate form of HBcAg rather than a linear contiguous amino acid sequence. Further, the detailed surface of the particles of the truncated and fulllength HBcAg molecules (26) must be very similar because the ligand binds the two structures with similar affinities.
A Peptide Ligand for HBcAg. Can the hexapeptide LL-GRMK bind HBcAg in the absence of the gpIII protein context of the filamentous phage? Fig. 1C shows that the 18/7) exhibited 50% inhibition at a concentration of "350 ,uM (Fig. 1D ). This result shows that neither the hydrophobic amino nor the hydrophilic carboxyl half of peptide ALL-GRMKG alone is sufficient for binding to HBcAg, but both regions play a role in complex formation. The hexapeptide LLGRMK may, therefore, be a mimic of internal regions of HBsAg that contact HBcAg and which include amino acids of HBsAg which are near to each other in the folded protein but separated in primary sequence. All the sequences selected for HBcAg binding exhibited a net charge of +2, suggesting that a basic region of HBsAg may contact an acidic external area of the nucleocapsid.
HBsAg L Polypeptide Forms a Complex with HBcAg. The hypothesis that the sequences selected for binding to HBcAg represent a mimotope of the HBV envelope proteins was tested in an assay designed to resemble a stage of morphogenesis involving the association of HBcAg with HBsAg. HBcAg and the 22-nm particles of HBsAg interact poorly, if at all, as judged by sedimentation analysis (K.M., and D. Hubsch, unpublished data) and so our assay involved the synthesis of either L or S HBsAg by in vitro translation and the association of these nascent products with HBcAg. L and S forms of HBsAg were translated from transcripts from a DNA template in a rabbit reticulocyte lysate, supplemented with [35S]methionine, in the presence or absence of microsomal vesicles. In the presence of microsomes, translation of S HBsAg mRNA produced bands on SDS/PAGE (Fig. 2A, lane 2) of 24 kDa and 27 kDa, corresponding to the unglycosylated and glycosylated forms of the S form, and translation of L HBsAg mRNA gave a predominant band at 39 kDa, corresponding to the unglycosylated protein, and a fainter band at 42 kDa, corresponding to the glycosylated form ( Fig. 2A, lane 4) . The glycosylated polypeptides were not obtained in the absence of microsomes. The glycosylated L and S sequences are the same size as those found in native HBV, indicating similar topology, with respect to the membrane, to the natural forms, in accord with a recent report (27) .
Translation reactions were carried out in the presence or absence of HBcAg, and the products were immunoprecipitated with anti-HBcAg polyclonal rabbit serum. L polypeptide was precipitated with anti-HBcAg only in the presence of HBcAg, demonstrating complex formation between the newly synthesized membrane-bound L polypeptide and HBcAg (Fig. 2B, lane 5) and that this step could be separated from other stages of viral assembly. The L polypeptide was still able to form a complex with HBcAg in the absence of microsomal v.esicles (Fig. 2B, lane 11) , suggesting that the pre-S regions of the L polypeptide may constitute an independently folded domain, not requiring insertion of the S region into a membrane for its ability to bind to HBcAg. In contrast, the S form was not precipitated with anti-HBcAg in the presence of HBcAg (Fig. 2B, lane 8) . Included as a positive control, both L and S polypeptides were precipitated with anti-HBsAg polyclonal rabbit sera (Fig. 2B, lanes 1-4) .
Because HBcAg bound L HBsAg, but did not bind S HBsAg, complex formation must involve the pre-S domain. Fig. 3 illustrates diagramatically the S-domain topology in the membrane (27) (28) (29) (30) Inhibitors of the Association of HBsAg with HBcAg. The assay system developed for inhibitors of the interaction between HBsAg and HBcAg involved incubating purified membrane-inserted 35S-labeled L polypeptide in HBcAg-coated wells and quantitating bound protein by scintillation counting. The specificity of this interaction was established through its inhibition by various antibodies. Fig. 4A shows that antiHBcAg polyclonal serum inhibited the association of L HBsAg with HBcAg at a two-logarithmic higher dilution than preimmunized polyclonal serum from the same rabbit. Polyclonal serum raised against denatured S HBsAg inhibited the association reaction at a 1.5-logarithm-higher dilution than polyclonal serum against the native S HBsAg. The principal target for polyclonal antibodies to the native, particulate S HBsAg resides between aa 110 and aa 150 (31) (32) (33) . That antisera against denatured S HBsAg effectively inhibited the interaction between HBcAg and L HBsAg, whereas antibodies to native (S) HBsAg do not, probably reflects the presence of antibodies specific for cytoplasmically disposed epitopes of the membrane-bound S HBsAg that are normally hidden in the native form. Interestingly, the most effective inhibitor of the interaction between the two antigens was a monoclonal anti- body (18/7) specific for a region close to the amino terminus of the pre-Si domain, aa 20-23 (4, 34) , not previously thought necessary for virus formation (35) . However, large molecules, such as immunoglobulins, can cause steric hindrance over a considerable distance in any compound to which they bind.
The synthetic peptide ALLGRMKG, identified as a ligand to HBcAg via the fusion phage library, inhibited the reaction between the L HBsAg and HBcAg with 50% inhibition observed at a peptide concentration of 10 ,uM (Fig. 4B) . The peptides GRMKG and ALLTRILG (the latter including aa 21-27 of the S region) exhibited no inhibitory properties, in accord with their inability to inhibit binding of fusion phage to HBcAg. However, LDPAFR, which includes the epitope (residues 20-23) recognized by a monoclonal antibody (18/7) to the pre-Sl domain, did inhibit, but with a half-maximal effect at -360 ,uM.
The results provide evidence that sequences selected from the fusion phage library for binding to HBcAg do, indeed, mimic cytoplasmic regions of L HBsAg. Taken together with the observation of inhibition by monoclonal antibody 18/7, or a peptide containing its epitope, these results show that at least part of the contact region for HBcAg lies within the pre-Si domain (Fig. 3) In addition to contributing to our understanding of HBV morphogenesis, the selected peptide ALLGRMKG may represent a lead antiviral agent targeted at the inhibition of viral assembly; we are attempting to evaluate this in transformed hepatoma cells that produce the virus. Such compounds could be useful in chronic infections. The search for effective therapeutic agents against diseases associated with HBV has become more urgent with the recent emergence of escape mutants of HBV (36) that are not neutralized by vaccineinduced antibodies. These approaches are encouraged by the recent demonstration that peptides taken from viral components can inhibit influenza (37) , sindbis, and vesicular stomatitis (38) virus formation.
